Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36378102.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2793 and PMC identifier 9852066.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Promising utility of using serial ctDNA in metastatic colorectal cancer to both refine patient selection, reduce toxicity due to chemotherapy, and to evaluate emerging resistance mechanisms may lead the way to novel therapeutic strategies. However, important questions remain in validating its use as a predictive biomarker of treatment response. See related article by Vidal et al., p. 379.
Medical subject headings
- Circulating Tumor DNA
- Rectal Neoplasms
- Colorectal Neoplasms